1.46
0.00 (0.00%)
| Previous Close | 1.46 |
| Open | 1.47 |
| Volume | 402,302 |
| Avg. Volume (3M) | 912,534 |
| Market Cap | 158,090,272 |
| Price / Sales | 7.71 |
| Price / Book | 1.14 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Operating Margin (TTM) | -1,222.27% |
| Diluted EPS (TTM) | -1.59 |
| Quarterly Revenue Growth (YOY) | -39.30% |
| Total Debt/Equity (MRQ) | 1.72% |
| Current Ratio (MRQ) | 5.06 |
| Operating Cash Flow (TTM) | -12.32 M |
| Levered Free Cash Flow (TTM) | -52.41 M |
| Return on Assets (TTM) | -18.20% |
| Return on Equity (TTM) | -91.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Aclaris Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.63 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 2.69% |
| % Held by Institutions | 88.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bollard Group Llc | 31 Mar 2025 | 1,424,176 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (HC Wainwright & Co., 995.89%) | Buy |
| Median | 9.00 (516.44%) | |
| Low | 8.00 (Wedbush, 447.95%) | Buy |
| Average | 11.00 (653.43%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Jun 2025 | 16.00 (995.89%) | Buy | 1.52 |
| 14 May 2025 | 16.00 (995.89%) | Buy | 1.18 | |
| Wedbush | 28 May 2025 | 8.00 (447.95%) | Buy | 1.41 |
| Scotiabank | 09 May 2025 | 9.00 (516.44%) | Buy | 1.26 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Jun 2025 | Announcement | Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference |
| 23 Jun 2025 | Announcement | Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 |
| 02 Jun 2025 | Announcement | Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis |
| 28 May 2025 | Announcement | Aclaris Therapeutics to Participate in Two June Healthcare Conferences |
| 09 May 2025 | Announcement | Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series |
| 08 May 2025 | Announcement | Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 29 Apr 2025 | Announcement | Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer |
| 22 Apr 2025 | Announcement | Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |